アルティミュン
Altimmune, Inc.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.12 | $0 | -$24M |
| 2026 Q1 | -0.18 | $0 | -$21M |
| 2025 Q4 | -0.27 | $26,000 | -$19M |
| 2025 Q3 | -0.21 | $5,000 | -$12M |
| 2025 Q2 | -0.27 | $5,000 | -$19M |
| 2025 Q1 | -0.26 | $5,000 | -$17M |
| 2024 Q4 |
| -0.33 |
| $5,000 |
| -$18M |
| 2024 Q3 | -0.32 | $5,000 | -$27M |